Home The implementation of a chronic disease management program (Prolanis) in Indonesia: a literature review
Article
Licensed
Unlicensed Requires Authentication

The implementation of a chronic disease management program (Prolanis) in Indonesia: a literature review

  • Sesty Rachmawati , Hanni Prihhastuti-Puspitasari and Elida Zairina EMAIL logo
Published/Copyright: December 20, 2019

Abstract

Background

The Chronic Disease Management Program or Program Pengelolaan Penyakit Kronis (Prolanis) is a program initiated by the Social Insurance Administration Organization or Badan Penyelenggara Jaminan Social (BPJS) in Indonesia. Prolanis aim to provide a proactive healthcare service approach for patients with chronic diseases particularly those with diabetes mellitus and hypertension. Prolanis also aims to achieve the optimal quality of life in patients with chronic disease through effective and efficient healthcare services including cost. All primary healthcare centers and a few of the private clinics in Indonesia have implemented Prolanis, however, the impact of the program has not been reviewed. This review aimed to see the implementation of Prolanis in healthcare facilities in Indonesia.

Methods

A literature review was conducted by searching articles through Google Scholar and PubMed databases up to August 2019. The following keywords or terms were used: Prolanis, BPJS indexed with terms related to blood pressure or hypertension in Indonesia. The references, citations and similar articles from the identified articles were used to identify additional sources.

Results

Twenty-four articles were identified through the first search using the key terms although only eight articles met the inclusion criteria. This review showed that the implementation of Prolanis in the healthcare facilities in Indonesia was varied in terms of the activities and services provided. The healthcare professional involved in the implementation of Prolanis were also varied. There were some barriers faced by the healthcare facilities including the availability of funding, the healthcare facilities and infrastructures, the unavailability of standard operating orocedures (SOPs) as well as the limitation of human resources involved in Prolanis.

Conclusions

The implementation of Prolanis in Indonesia has not been optimized, as there were some barriers during its implementation in the healthcare facilities.

Acknowledgment

This paper has been presented at the 8th APPEN Conference and the 2nd HPC Conference on 8-9 October 2019, Universitas Airlangga, Surabaya, Indonesia.

  1. Research funding: None declared.

  2. Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

  3. Competing interests: Authors state no conflict of interest.

References

[1] WHO (World Health Organization). 2008–2013 Action plan for the global strategy for the prevention and control of communicable diseases. Geneva: WHO, 2008.Search in Google Scholar

[2] The Ministry of Health of Indonesia. Riset Kesehatan Dasar. Jakarta: Badan Penelitian dan Pengembangan Kesehatan, 2018.Search in Google Scholar

[3] Kinanti AA. Menkes Sebut Dana BPJS Banyak Diserap Hipertensi 2017. . Available at: https://health.detik.com/berita-detikhealth/d-3446688/menkes-sebut-dana-bpjs-kesehatan-banyak-diserap-hipertensi?_ga=2.187586848.941299295.1574035937-15235773.1574035937. Accessed: 4 Nov 2019.Search in Google Scholar

[4] Badan Penyelenggara Jaminan Sosial Kesehatan. Panduan Praktis Prolanis (Program Pengelolaan Penyakit Kronis). BPJS Kesehatan 2014:3–6. DOI: 10.1117/12.497904.Search in Google Scholar

[5] Badan Penyelenggara Jaminan Sosial Kesehatan. Peraturan Bersama Sekretaris Jenderal Kementerian Kesehatan Republik Indonesia Dan Direktur Utama Badan Penyelenggara Jaminan Sosial Kesehatan Nomor HK. 01.08/III/980/2017 Tahun 2017 Nomor 2 Tahun 2017 Tentang Petunjuk Teknis Pelaksanaan Pembayaran Kapitasi Berbasis Pemenuhan Komitmen Pelayanan Pada Fasilitas Kesehatan Tingkat Pertama. Jakarta, 2017.Search in Google Scholar

[6] Kementerian Kesehatan Republik Indonesia. Peraturan Menteri Kesehatan Republik Indonesia Nomor 71 Tahun 2013 Tentang Pelayanan Kesehatan Pada Jaminan Kesehatan Nasional. Jakarta: Kementerian Kesehatan Republik Indonesia, 2013.Search in Google Scholar

[7] Badan Penyelenggara Jaminan Sosial Kesehatan. Peraturan Badan Penyelenggara Jaminan Sosial Kesehatan Nomor 2 Tahun 2015 Tentang Norma Penetapan Besaran Kapitasi dan Pembayaran Kapitasi Berbasis Pemenuhan Komitmen Pelayanan Pada Fasilitas Kesehatan Tingkat Pertama. Jakarta, 2015.Search in Google Scholar

[8] Assupina M, Rahmiwati A. Analysis of implementation of the chronic disease management program (Prolanis) at family doctors of PT Askes in Palembang on 2013. J Ilmu Kesehatan Masyarakat 2013;254–61.Search in Google Scholar

[9] Anita M. Implementation of chronic disease program (Prolanis) in patients with hypertension in Puskesmas Jetis Yogyakarta. J Kebijakan Kesehatan Indonesia 2019;8:51–8.Search in Google Scholar

[10] Ria NU. Input Program Pengelolaan Penyakit Kronis di Puskesmas. J Higeia Public Health Res Dev 2019;3:63–73.Search in Google Scholar

[11] Nasution NM. Implementasi Program Pengelolaan Penyakit Kronis (Prolanis) di Puskesmas Kedai Durian Medan Johor Tahun 2018. Repositori Institusi USU. 2018. Available at: http://repositori.usu.ac.id/handle/123456789/11343Search in Google Scholar

[12] Sitompul S, Suryawati C, Wigati PA. Analisis Pelaksanaan Program Pengelolaan Penyakit Kronis (Prolanis) BPJS Kesehatan Pada Dokter Keluarga di Kabupaten Pekalongan Tahun 2016. Jurnal Kesehatan Masyarakat (e-Journal) 2016;4:145–53.Search in Google Scholar

[13] Ramsar U, Trisnantoro L, Putri LP. Implementation of chronic disease management (Prolanis) program in Puskesmas Poasia Kendari. J Kebijakan Kesehatan Indonesia 2017;6:200–3.Search in Google Scholar

[14] Rosdiana AI, Raharjo BB, Indarjo S. Implementasi Program Pengelolaan Penyakit Kronis (Prolanis). J Higeia Public Health Res Dev 2017;1:140–50.Search in Google Scholar

[15] Latifah I, Maryati H. Analisis Pelaksanaan Program Pengelolaan Penyakit Kronis (Prolanis) BPJS Kesehatan Pada Pasien Hipertensi di UPTD Puskesmas Tegal Gundil Kota Bogor. Hearty J Kesehatan Masyarakat 2019;6:1–11. DOI: 10.32832/hearty.v6i2.1277.Search in Google Scholar

Received: 2019-11-18
Accepted: 2019-11-25
Published Online: 2019-12-20

© 2019 Walter de Gruyter GmbH, Berlin/Boston

Articles in the same Issue

  1. Reviews
  2. Pharmacist contributions in the treatment of diabetes mellitus in Southeast Asia: a narrative review
  3. The implementation of a chronic disease management program (Prolanis) in Indonesia: a literature review
  4. Original Articles
  5. Quercetin attenuates acute predator stress exposure-evoked innate fear and behavioral perturbation
  6. Evaluating current practices and policies in the use of injectable medicines for treating myalgia in a primary care center in Pamekasan, Indonesia
  7. The contemporary role and potential of pharmacist contribution for community health using social media
  8. Evaluation of rational drug use based on World Health Organization prescribing indicators in a primary care center in Pamekasan East Java, Indonesia
  9. The prescription patterns of second-generation antipsychotics in schizophrenia outpatient setting
  10. Factors affecting community pharmacist’s service for women with chronic diseases during pregnancy and breastfeeding: application of the Health Belief Model
  11. Overview of therapeutic changes in antiepileptic drugs in adult patients
  12. Exploration of barriers affecting job satisfaction among community pharmacists
  13. Patients’ characteristics and their adherence to insulin therapy
  14. Correlation of chemotherapy costs with quality of life in nasopharyngeal cancer patients
  15. Impact of educational preeclampsia prevention booklet on knowledge and adherence to low dose aspirin among pregnant women with high risk for preeclampsia
  16. Translation, cultural adaptation, and validation of the quality of well being self-administered questionnaire in general population in Indonesia
  17. Knowledge, attitude, and practice of pharmacists towards management of hypertension in primary care centers
  18. Medication adherence in diabetes mellitus patients at Tanjung Karang Primary Health Care Center, Mataram
  19. Decreasing angiogenesis vasa vasorum through Lp-PLA2 and H2O2 inhibition by PSP from Ganoderma lucidum in atherosclerosis: in vivo diabetes mellitus type 2
  20. Antiaggregation effect of clopidogrel in coronary heart disease patients using omeprazole
  21. The effect of curcuma (Curcuma xanthorrizha roxb.) extract as an adjuvant of captopril therapy on cardiac histopathology of male mice (Mus musculus) with hypertension
  22. Coenzyme Q10 nanostructured lipid carriers as an inducer of the skin fibroblast cell and its irritability test in a mice model
  23. Medical problems in patients with chronic kidney disease undergoing hemodialysis and their therapy
  24. ADMET properties of novel 5-O-benzoylpinostrobin derivatives
  25. Development of nonalcoholic fatty liver disease model by high-fat diet in rats
  26. Molecular docking of novel 5-O-benzoylpinostrobin derivatives as wild type and L858R/T790M/V948R mutant EGFR inhibitor
  27. The relationship between the level of education and accuracy of insulin injection techniques in DM patients with measurement of HbA1c values
  28. The effect of premixed insulin to blood glucose concentration in patients with type 2 diabetes mellitus
  29. Intravenous insulin therapy in diabetes mellitus with hyperglycemic crisis and intercurrent illness
  30. Adherence behavior assessment of oral antidiabetic medication use: a study of patient decisions in long-term disease management in primary health care centers in Surabaya
  31. Evaluation to the chemotherapy use in patients with diffuse large B-cell lymphoma
  32. Analysis of the use and cost of stress ulcer prophylaxis for surgical inpatients
  33. Antineuroinflammation activity of n-butanol fraction of Marsilea crenata Presl. in microglia HMC3 cell line
  34. The enhancement of Arg1 and activated ERβ expression in microglia HMC3 by induction of 96% ethanol extract of Marsilea crenata Presl. leaves
  35. Ternary solid dispersion to improve solubility and dissolution of meloxicam
  36. Improving solubility and dissolution of meloxicam by solid dispersion using hydroxypropyl methylcellulose 2910 3 cps and nicotinamide
  37. o-Hydroxycinnamic derivatives as prospective anti-platelet candidates: in silico pharmacokinetic screening and evaluation of their binding sites on COX-1 and P2Y12 receptors
  38. The change of proinflammatory cytokine tumor necrosis factor α level in the use of meloxicam in rat model of osteoarthritis
  39. Attenuation of IL-1ß on the use of glucosamine as an adjuvant in meloxicam treatment in rat models with osteoarthritis
  40. Analysis of effectiveness and drug related problems of pain reliever for knee osteoarthritis: weighing clinical risk and benefit
  41. Comparison of antibiotic prescriptions in adults and children with upper respiratory tract infections in Bangka Tengah primary health care centers
  42. Profile of sociodemographics, sources of infection, antiretrovirals and CD4 counts on HIV/AIDS outpatients in Turen Primary Health Centre, Indonesia
  43. Synergistic anti-hepatitis C virus activity of Ruta angustifolia extract with NS3 protein inhibitor
  44. In vitro equivalence of generic and branded amoxicillin tablet by microbiological assay method
  45. Knowledge and attitude: two fundamental factors that determine patient compliance in antibiotic therapy
  46. Molecular docking study of sappan wood extract to inhibit PBP2A enzyme on methicillin-resistant Staphylococcus aureus (MRSA)
  47. Effect of curcumin analogue synthetic product from cullilawan oil for the liver damage treatment in male mice (Mus musculus L.)
  48. Case Report
  49. A case report of generalized tetanus in a 42-year-old man with dental infection
Downloaded on 14.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/jbcpp-2019-0350/html
Scroll to top button